Precision medicine in systemic lupus erythematosus

Parodis highlights the emergence of approved targeted therapies, such as belimumab and anifrolumab, along with the recent approval of voclosporin for lupus nephritis. He emphasizes the importance of understanding the underlying mechanisms of SLE and its various clinical phenotypes. He anticipates a paradigm shift from traditional taxonomies towards molecular characterization of the disease. Parodis also shares his recent research on gene module analysis, where patients with lupus nephritis were grouped based on their interferon signature (low, intermediate, and high) and studied for their response to different therapies based on systems biology. Understanding which genetic signatures can be altered by targeting specific genes will allow us to apply targeted therapies more effectively in a personalized manner in the future.